Study: CBD Administration Associated With Improved Quality Of Life In Patients With Parkinson’s DiseaseSeptember 25, 2014
The administration of cannabidiol (CBD), a nonpsychotropic cannabinoid, is associated with improved quality of life in patients with Parkinson’s disease, according clinical trial data published online ahead of print in the Journal of Psychopharmacology.
Investigators at the University of São Paulo in Brazil assessed the efficacy of CBD versus placebo in 21 subjects with Parkinson’s. Authors reported that the administration of 300 mg doses of CBD per day was associated with “significantly different mean total scores” in subjects’ well-being and quality of life compared to placebo.
Separate assessments of CBD versus placebo reported that the cannabinoid did not appear to mitigate general symptoms of the disease, nor was it shown to be neuroprotective.
“This study points to a possible effect of CBD in improving measures related to the quality of life of PD patients without psychiatric comorbidities,” investigators concluded. They added, “We found no statistically significant differences concerning the motor symptoms of PD; however, studies involving larger samples and with systematic assessment of specific symptoms of PD are necessary in order to provide stronger conclusions regarding the action of CBD in PD.”
Clinical reports have previously indicated that both CBD and/or whole-plant cannabis may address various symptom’s of Parkinson’s disease, including improvement in motor symptoms, pain reduction, improved sleep, and a reduction in the severity of psychotic episodes.
Survey data of patients with PD indicates that almost half of all subjects who try cannabis report experiencing subjective relief from the plant.
The abstract of the study, “Effects of cannabidiol in the treatment of patients with Parkinson’s disease: An exploratory double-blind trial,” appears online here.
Marijuana use by newly married couples is predictive of less frequent incidences of intimate partner violence perpetration, according to longitudinal data published online ahead of print in the journal Psychology of Addictive Behaviors.
Investigators at Yale University, Rutgers, and the University of Buffalo assessed over 600 couples to determine whether husbands’ and wives’ cannabis use was predictive of domestic abuse at any time during the first nine years of marriage. Researchers reported: “In this community sample of newly married couples, more frequent marijuana use generally predicted less frequent IPV perpetration, for both men and women, over the first 9 years of marriage. Moderation analyses provided evidence that couples in which both spouses used marijuana frequently were at the lowest risk for IPV perpetration, regardless of the perpetrator’s gender.”
Stated the study’s lead author in a press release: “Although this study supports the perspective that marijuana does not increase, and may decrease, aggressive conflict, we would like to see research replicating these findings, and research examining day-to-day marijuana and alcohol use and the likelihood to IPV on the same day before drawing stronger conclusions.”
According to a previous study, published in January in the journal Addictive Behaviors, alcohol consumption — but not cannabis use — is typically associated with increased odds of intimate partner violence. Authors reported: “On any alcohol use days, heavy alcohol use days (five or more standard drinks), and as the number of drinks increased on a given day, the odds of physical and sexual aggression perpetration increased. The odds of psychological aggression increased on heavy alcohol use days only.” By contrast, researchers concluded that “marijuana use days did not increase the odds of any type of aggression.”
The abstract of the study, “Couples’ marijuana use is inversely related to their intimate partner violence over the first 9 years of marriage,” is online here.
The enactment of medicinal marijuana laws is associated with significantly lower state-level opioid overdose mortality rates, according to data published online today in the Journal of the American Medical Association (JAMA) Internal Medicine.
A team of investigators from the University of Pennsylvania, the Albert Einstein College of Medicine in New York City, and the Johns Hopkins Bloomberg School of Public Health in Baltimore conducted a time-series analysis of medical cannabis laws and state-level death certificate data in the United States from 1999 to 2010 — a period during which 13 states instituted laws allowing for cannabis therapy.
Researchers reported, “States with medical cannabis laws had a 24.8% lower mean annual opioid overdose mortality rate compared with states without medical cannabis laws.” Specifically, overdose deaths from opioids decreased by an average of 20 percent one year after the law’s implementation, 25 percent by two years, and up to 33 percent by years five and six.
They concluded, “In an analysis of death certificate data from 1999 to 2010, we found that states with medical cannabis laws had lower mean opioid analgesic overdose mortality rates compared with states without such laws. This finding persisted when excluding intentional overdose deaths (ie, suicide), suggesting that medical cannabis laws are associated with lower opioid analgesic overdose mortality among individuals using opioid analgesics for medical indications. Similarly, the association between medical cannabis laws and lower opioid analgesic overdose mortality rates persisted when including all deaths related to heroin, even if no opioid analgesic was present, indicating that lower rates of opioid analgesic overdose mortality were not offset by higher rates of heroin overdose mortality. Although the exact mechanism is unclear, our results suggest a link between medical cannabis laws and lower opioid analgesic overdose mortality.”
In a written statement to Reuters Health, lead author Dr. Marcus Bachhuber said: “Most of the discussion on medical marijuana has been about its effect on individuals in terms of reducing pain or other symptoms. The unique contribution of our study is the finding that medical marijuana laws and policies may have a broader impact on public health.”
Added co-author Colleen L. Barry in USA Today: “[The study’s findings] suggest the potential for many lives to be saved. … We can speculate … that people are completely switching or perhaps supplementing, which allows them to lower the dosage of their prescription opioid.”
Nationwide, overdose deaths involving opioid analgesics have increased dramatically over the past decade. While fewer than 4,100 opiate-induced fatalities were reported for the year 1999, by 2010 this figure rose to over 16,600 according to an analysis by the US Centers for Disease Control.
An abstract of the JAMA study, “Medical Cannabis Laws and Opioid Analgesic Overdose Mortality in the United States, 1999-2010,” appears online here.
The administration of a single dose of whole-plant cannabis via a thermal-metered inhaler is effective and well tolerated among patients suffering from neuropathy (nerve pain), according to clinical trial data published online ahead of print in the Journal of Pain and Palliative Care Pharmacotherapy.
Israeli investigators assessed the efficacy of a novel, portable metered-dose cannabis inhaler in eight subjects diagnosed with chronic neuropathic pain. Researchers reported that the device administered an efficient, consistent, and therapeutically effective dosage of cannabinoids to all participants.
They concluded, “This trial suggests the potential use of the Syqe Inhaler device as a smokeless delivery system of medicinal cannabis, producing a delta-9-THC pharmacokinetic profile with low inter-individual variation of (maximum drug/plasma concentrations), achieving pharmaceutical standards for inhaled drugs.”
A series of clinical trials conducted by investigators affiliated with the Center for Medicinal Cannabis Research at the University of California, San Diego previously determined that the inhalation of whole-plant cannabis is efficacious in the treatment of neuropathic pain.
Full text of the study, “The pharmacokinetics, efficacy, safety, and ease of use of a novel portable metered-dose cannabis inhaler in patients with chronic neuropathic pain: A phase 1a study,” will appear in the Journal of Pain and Palliative Care Pharmacotherapy.
While the US government effectively bans scientific research regarding cannabis and any potential therapeutic uses, you can help University of Texas at Dallas associate professor of Criminology Dr. Robert Morris, II conduct another in a series of cannabis policy research-related questions.
This time around Dr. Morris and his colleagues are asking the sensible question public policy question: ‘Does Medical Cannabis Legalization Impact Police Officer Safety?’
NORML’s curious, aren’t you too?
Let’s help fund the research via crowdsourcing and find out the important answer to the above question after the data is gathered, crunched, analyzed and published.
Thanks for advancing science and public policy making in America regarding cannabis!
*The answer from the paper on medical cannabis’ impact on violent crime rates: ‘no’, violent crime rates do not rise because of the presence of medical cannabis retail stores.